Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 20, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:23 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1147

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 997–1008 of 1,147 matching trials for Lung Cancer.

Indexed local directory records.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search

Conditions: Cancer Survivors, Lung Cancer
Interventions: Targeted-telerehabilitation, Waitlist; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer, Non Small Cell Lung Cancer
Interventions: Abemaciclib, Anastrozole, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Lung Cancer
Interventions: Centralized Screening Unit Implementation; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years to 77 Years
Enrollment: 9,460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Pulmonary Artery-First Surgical Technique; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 4
States / cities: Abington, Pennsylvania • Philadelphia, Pennsylvania • Willow Grove, Pennsylvania

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: APL-101, Osimertinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer, Lung Transplant, Thoracic Diseases
Interventions: Tissue Banking; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Gastroesophageal Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Muscle Invasive Bladder Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Uterine Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Early Stage Non-Small Cell Lung Cancer
Interventions: Precision hypofractionated radiation, Vancomycin; Radiation · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Urothelial Carcinoma
Interventions: N-803 + Atezolizumab, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Docetaxel + Nivolumab, N-803 + Docetaxel + Pembrolizumab, N-803 + Durvalumab, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Nivolumab, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Pembrolizumab, N-803 + Pembrolizumab + PD-L1 t-haNK; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 35
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more

Conditions: Lung Cancer, Lung Diseases, Lung Diseases, Interstitial, Lung Diseases, Obstructive, Lung Inflammation
Interventions: Observational only, all subjects; measure DNA mutation and proteomic survey.; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: CRC (Colorectal Cancer), HCC - Hepatocellular Carcinoma, MSI-H Cancer, NSCLC Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Solid Tumor, Adult, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer)
Interventions: Decoy20, Tislelizumab; Drug
Lead sponsor: Indaptus Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more

Conditions: Limited-Stage Small Cell Lung Cancer
Interventions: HLX10, Placebo, Prophylactic Cranial Irradiation (PCI), Thoracic radiotherapy, carboplatin/cisplatin-etoposide; Drug · Radiation
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Stored official records

Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Centralized Screening Unit (CSU) at Montefiore-Einstein

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Thoracic Specimen Registry

Sample Collection for Ongoing Research and Product Evaluation Study

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Cough Capture as a Portal Into the Lung

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

About this Lung Cancer clinical trials directory page